GlassScriptPhysician profile
Alan Zakko
NPI 1982194130
$1,117.21
in general payments reported to CMS, 2019-2025
10 companies · $639 in 2025
The $639 reported for 2025 was more than what 92% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $478 · 2025: $639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,117.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $275.00 | 2024 | Voquezna |
| Abbvie INC. | $169.83 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $150.00 | 2025 | Iqirvo |
| Gilead Sciences, INC. | $135.00 | 2025 | Livdelzi |
| Janssen Scientific Affairs, LLC | $127.91 | 2025 | Tremfya |
| Madrigal Pharmaceuticals | $102.25 | 2025 | Rezdiffra |
| Janssen Biotech, INC. | $79.78 | 2024-2025 | Tremfya, Stelara |
| Boston Scientific Corporation | $33.32 | 2025 | Resolution 360 Clip |
| Mallinckrodt Hospital Products INC. | $23.60 | 2024 | Terlivaz |
| Takeda Pharmaceuticals U.S.A., INC. | $20.52 | 2025 | Entyvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Zakko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.